cancer, 42% response rates with androgen deprivation therapy (leuprorelin and bicalutamide) were seen. 5 The most dramatic gains have been reported in NTRK3 rearranged mammary analogue secretory carcinoma, with 75% response rates in a non-randomised trial of pan-Trk inhibition with larotrectinib in patients harbouring this gene rearrangement irrespective of primary tumour site. 6 Here we review clinical trials currently recruiting patients with salivary gland cancer and describe the potential for tumour profiling to stratify patients for trials targeting molecular sub-groups. We then discuss the potential future application of next generation sequencing in salivary gland cancer to inform clinical decision making.
| ME TH ODS
To identify clinical trials currently recruiting patients with salivary gland cancer, a search of www.clinicaltrials.gov was performed using the search terms "head and neck cancer," "salivary gland cancer,"
"salivary duct carcinoma," adenoid cystic carcinoma," "mammary analogue secretory carcinoma," "acinic cell carcinoma," "myoepithelial carcinoma," "cancer AND (matched OR basket OR actionable)". Results were limited to trials which were both "currently recruiting" and "interventional" and 12 The combination of PDL1 and CTLA4 blockade has shown increased clinical efficacy over either approach alone in melanoma, 11 and three studies assessing the combination of nivolumab with the CTLA4 blocking antibody ipilimumab are now underway in salivary gland cancer (NCT03172624, NCT02834013 and NCT03146650).
As with the studies of nivolumab, these studies are for patients with The abscopal effect describes the phenomenon through which radiotherapy to one site of disease can lead to regression of lesions at distant sites. It is proposed that combining immunotherapy with radiotherapy could therefore augment the abscopal effect. 13 In addition, as radiation causes immunogenic cell death, it is proposed that radiation treatment can augment immune checkpoint blockade.
These hypotheses are being evaluated in a randomised phase two study of pembrolizumab with or without radiation in 44 patients with metastatic ACC (NCT03087019) with the primary end-point of response in non-irradiated (ab scopal) lesions.
Vorinostat is a histone deacetylase (HDAC) inhibitor, first approved for clinical use in cutaneous T-cell lymphoma. 14 
Keypoints
• Our systematic review identified 20 trials for patients with salivary gland cancer.
• The majority of trials included no molecular stratification.
• Advances in next generation sequencing enable molecular profiling to select patients for trial therapy.
• Laboratory studies are required to determine the functional significance of molecular alterations in salivary gland cancer.
(NCT02883374) with the primary end-point of disease control rate.
HDAC inhibition has been shown to sensitise ACC cells in vitro to cisplatin chemotherapy 17 and future clinical studies would be required to evaluate this combination in patients.
| Clinical trials with molecular stratification
Two sub-types of salivary gland cancer are currently the subject of molecularly targeted trials. These are AR positive salivary duct carcinoma and NTRK3 rearranged mammary analogue secretory carcinoma. Basket trials, a tumour agnostic approach to drug development in which patients, are allocated to a targeted therapy based on the presence of a specific molecular abnormality, irrespective of tumour histology, represent an interesting approach for patients with salivary gland cancers. Response rate demonstrated to overcome acquired resistance to Trk inhibition, 21 and this is being studied in patients who have progressed on prior Trk kinase inhibitor therapy (NCT03215511).
| Androgen receptor overexpression

| Basket studies including molecular profiling and multiple treatment arms
Other individual genetic alterations are infrequent events across salivary gland cancer sub-types 22, 23 
| Utility of molecular profiling of salivary gland cancer patients to stratify for clinical trials
The broader question of impact on of molecular profiling in guiding targeted therapies has been addressed across advanced cancers. [24] [25] [26] The Memorial Sloan Kettering IMPACT study 24 
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